Please assess the completion status of the following clinical trial:

Trial Title: Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of perennial allergic rhinitis, asthma, or both for a minimum of 1 year prior to study entry;~* Positive skin prick test to German cockroach;~* No known contraindications to therapy with glycerinated German cockroach allergenic extract or placebo; and~* Willing to sign the written Informed Consent prior to initiation of any study procedures.~Exclusion Criteria:~* Cannot perform spirometry at screening;~* Have clinically significant abnormal laboratory values;~* Have an Asthma classification of severe persistent at screening;~* Hospitalized for asthma within the 6 months prior to study entry;~* Life-threatening asthma exacerbation that required intubation, mechanical ventilation, or that resulted in a hypoxic seizure within the 2 years prior to study entry;~* No access to a telephone;~* Received allergen immunotherapy within the last 12 months prior to study entry and plan on initiating or resuming immunotherapy during the study;~* Treatment with anti-immunoglobulin E (anti-IgE) therapy within 1 year of study entry;~* Received an investigational drug within the 30 days prior to study entry and plan on using an investigational drug during the study;~* Experienced nausea, vomiting, abdominal pain or cramps, or diarrhea within the 3 months prior to study entry;~* Refuse to sign the Epinephrine Auto-injector Training Form;~* Does not primarily speak English;~* Plan to move from the area during the study period;~* History of idiopathic anaphylaxis or anaphylaxis grade 3;~* Using tricyclic antidepressants or beta-adrenergic blocker drugs;~* Clinically unacceptable complete blood count (CBC) and liver function tests, as defined by a hemoglobin less than 11.5 in males and 10.0 in females, or platelet counts less than 150,000 and an Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) greater than twice the upper limit of normal;~* Any condition that, in the opinion of the investigator, would interfere with the study; or~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Glycerinated German Cockroach Allergenic Extract (Type: EXPERIMENTAL): Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered concentrated (1:20 weight per volume \[w/v\]) daily doses of glycerinated German cockroach allergenic extract (50% glycerin) placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The extract was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
- Placebo (Type: PLACEBO_COMPARATOR): Participants with German cockroach allergy and mild to moderate asthma, rhinitis, or both self-administered daily doses of placebo placed under the tongue (sublingually) to dissolve. The treatment course and study duration was 6 months. Note: The placebo was also administered during the preliminary dosing visits, up to five escalating doses, or until the maximum study dose (420 microliters, 1:20 weight per volume \[w/v\]) was achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).